Status:
COMPLETED
Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Marijuana Abuse
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
During the past 15 years, the demand for treatment for marijuana-related problems in the United States has increased nearly twofold. Selegiline is a medication currently used to treat nicotine depende...
Detailed Description
Behavioral therapy paired with drug therapy might be a more effective treatment approach to marijuana dependence than behavioral therapy alone. Selegiline is a monoamine oxidase-B inhibitor. It increa...
Eligibility Criteria
Inclusion
- Meets DSM-IV criteria for current marijuana dependence
- Positive urine toxicology test for marijuana
- Reports current marijuana use
- Weighs at least 100 lbs
- Women of childbearing age will be included provided they agree to use adequate contraception
Exclusion
- Meets dependence or abuse criteria for alcohol
- Meets dependence criteria for illicit substances other than marijuana
- Serious medical disorders (such as unstable angina or liver failure), that may make participation in the trial unsafe
- Pregnant
- Currently diagnosed with a psychotic disorder
- Currently suicidal or pose a homicidal risk
- Currently taking over-the-counter (e.g., pseudoephedrine) or prescription (e.g., methylphenidate) sympathomimetic agents, antidepressant agents (e.g., tricyclic antidepressants, serotonin reuptake inhibitors, bupropion, other monoamine oxidase inhibitors), or meperidine (Demerol)
- Unable to understand English
- Known hypersensitivity to selegiline hydrochloride
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00218517
Start Date
March 1 2005
End Date
July 1 2007
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MRU
New Haven, Connecticut, United States, 06519